Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 17/20 | 0.71 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970895 | 1.00 | LPAR1 (0.71) | LPAR1LPAR2PTGDR2PPARGPPARA | |
| SCHEMBL969576 | 0.91 | LPAR1 (0.79) | LPAR1LPAR2 | |
| SCHEMBL969577 | 0.91 | LPAR1 (0.79) | LPAR1LPAR2 | |
| SCHEMBL2516761 | 0.91 | LPAR1 (0.79) | LPAR1LPAR2 | |
| SCHEMBL968665 | 0.86 | LPAR1 (0.86) | LPAR1LPAR2 | |
| SCHEMBL968667 | 0.86 | LPAR1 (0.86) | LPAR1LPAR2 | |
| SCHEMBL970293 | 0.85 | LPAR1 (0.78) | LPAR1 | |
| SCHEMBL970295 | 0.85 | LPAR1 (0.78) | LPAR1 | |
| SCHEMBL969597 | 0.84 | LPAR1 (0.73) | LPAR1 | |
| SCHEMBL969595 | 0.84 | LPAR1 (0.73) | LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695955-B1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1695955-A1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | LPAR2, LPAR1, LPAR5 | LPAR1 2/4885LPAR2 1/4885PTGDR2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.